New drug combo aims to delay ovarian cancer return in High-Risk patients
NCT ID NCT07472140
First seen Apr 07, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study is for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific genetic feature (HRD). The trial tests whether taking a combination of two drugs (a PARP inhibitor and an angiogenesis inhibitor) after initial treatment can help keep the cancer from returning. About 120 participants will be randomly assigned to receive the drug combination or standard care, and researchers will track how long they remain cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
N.N. Alexandrov National Caner Centre
RECRUITINGMinsk, Lesnoy, 223040, Belarus
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.